Emmaus Life Sciences Reports New Financial Obligations and Equity Sales
Ticker: EMMA · Form: 8-K · Filed: Feb 26, 2024 · CIK: 822370
| Field | Detail |
|---|---|
| Company | Emmaus Life Sciences, INC. (EMMA) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $9 million, $0.13 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, equity-sales, material-agreement
TL;DR
**Emmaus Life Sciences just took on new debt and sold more stock, signaling potential capital raising.**
AI Summary
Emmaus Life Sciences, Inc. entered into a Material Definitive Agreement and created a Direct Financial Obligation on February 21, 2024. This filing also reports Unregistered Sales of Equity Securities by the company. The company, based in Torrance, CA, operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates Emmaus Life Sciences is actively engaging in financial agreements and potentially raising capital through equity sales, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — The creation of a direct financial obligation and unregistered sales of equity securities can introduce both opportunities and risks, depending on the terms and use of proceeds.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Registrant
- February 21, 2024 (date) — Date of earliest event reported
- Torrance, CA (location) — Business address
- Delaware (location) — State of incorporation
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 21, 2024.
What type of agreements did Emmaus Life Sciences, Inc. enter into?
Emmaus Life Sciences, Inc. entered into a Material Definitive Agreement and created a Direct Financial Obligation.
What other financial activity was reported by Emmaus Life Sciences, Inc.?
The company also reported Unregistered Sales of Equity Securities.
Where is Emmaus Life Sciences, Inc. incorporated?
Emmaus Life Sciences, Inc. is incorporated in Delaware.
What is the business address of Emmaus Life Sciences, Inc.?
The business address of Emmaus Life Sciences, Inc. is 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-02-26 08:00:31
Key Financial Figures
- $9 million — ent pursuant to which we agree to issue $9 million principal amount of convertible promiss
- $0.13 — common stock at the conversion rate of $0.13 per share. The Exchange Notes will bear
Filing Documents
- ea0200618-8k_emmaus.htm (8-K) — 30KB
- ea0200618ex4-1_emmaus.htm (EX-4.1) — 163KB
- ea0200618ex10-1_emmaus.htm (EX-10.1) — 31KB
- ea0200618ex10-2_emmaus.htm (EX-10.2) — 5KB
- 0001213900-24-016715.txt ( ) — 440KB
- emma-20240221.xsd (EX-101.SCH) — 3KB
- emma-20240221_lab.xml (EX-101.LAB) — 33KB
- emma-20240221_pre.xml (EX-101.PRE) — 22KB
- ea0200618-8k_emmaus_htm.xml (XML) — 3KB
02 Unregistered Sale of Securities
Item 3.02 Unregistered Sale of Securities The information in Item 1.01 of this Report regarding the issuance of the Exchange Notes is hereby incorporated herein by reference. The Exchange Notes will be issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption from registration under Section 3(a)(9) of such Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which information is incorporated herein by reference. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 26 , 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 4.1 Form of Convertible Promissory Note Due February 24, 2025 10.1 Exchange Agreement dated as of February 21, 2024 10.2 Form of Joinder Agreement and Amendment to Transfer Restriction and Voting Agreement 10.3 Transfer Restriction and Voting Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K (File No. 001-35527) filed on February 16, 2021 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3